Challenge Your Exam Readiness With Our Free PANCE Practice Questions

COPD is diagnosed by post-bronchodilator FEV1/FVC <0.70. A reduced DLCO suggests emphysema-predominant disease. While bronchodilators (SABA, LABA, LAMA) improve symptoms and reduce exacerbations, the intervention with proven mortality benefit is long-term oxygen therapy (LTOT) for patients with chronic resting hypoxemia (PaO2 ≤55 mm Hg or SaO2 ≤88%, or PaO2 56–59 with cor pulmonale/polycythemia). LTOT for ≥15 hours/day improves survival, polycythemia, and pulmonary hypertension. SABAs provide relief but no mortality benefit. Theophylline has limited role due to narrow therapeutic index and side effects. Roflumilast (PDE-4 inhibitor) reduces exacerbations in chronic bronchitis with severe COPD but does not confer mortality benefit. Smoking cessation, vaccinations, pulmonary rehab, and correct inhaler technique are essential components of comprehensive management, aligning with pulmonary diagnostics and therapeutic objectives.